Devices

Get Strategic Intelligence from Device Warnings

Medical device manufacturers should be using FDA Warning Letters as a source of strategic intelligence that highlights recurring patterns, systemic gaps, and evolving priorities that can be used to strengthen compliance and drive operational excellence. That’s the view of “independent expert” Marcelo Trevino, writing in a MedDevice Online column.

Trevino writes that Warning Letters rarely come as a surprise since they typically are preceded by a form FDA-483 that documents objectionable conditions. What happens after the agency issues a 483 often determines whether it escalates into a formal Warning Letter, he says. Trevino says that both FDA investigators and industry experts stress that what leads to a Warning Letter is not the form FDA-483 itself but rather the company’s response to that communication.

“Companies can withstand the findings of an FDA inspection only if they respond swiftly and effectively to address the cited issues,” he says.

According to Trevino, common pitfalls in responding to FDA-483s that lead to Warning Letters are a superficial root cause analysis, inadequate or vague corrective actions, defensive or dismissive tone, and missed deadlines or a lack of response.

“A form FDA-483 response should be treated with the same rigor as a regulatory submission,” Trevino writes. “Cross-functional teams should work methodically to address every observation, performing comprehensive root cause analysis and developing strong corrective and preventive action plans…. Responding to a form 483 with clarity, accountability, and urgency can prevent a Warning Letter and protect both reputation and operations. Medical device manufacturers should think of the form 483 as the first alarm. If it is ignored or handled poorly, the fire that follows can damage the entire enterprise. Leaders must ensure these early warning signs are addressed at the highest standard.”

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome